The Jackson Laboratory has developed a new platform to provide a fast, accurate and reliable method for screening novel immunotherapy treatments for efficacy and cytokine release syndrome.

In a live virtual event, Attaya Suvannasankha, MD, discussed the MajesTEC-1 trial of teclistamab and approaches to mitigation ...

One concern is that insertional mutagenesis of the lentiviral DNA payload in in vivo CAR-Ts may cause secondary cancers.

Imdelltra is associated with improvement in overall survival compared to local standard-of-care chemotherapy among patients with small cell lung cancer.

Axi-cel, tisa-cel, and brexu-cel were found comparable to other cellular therapy experiences for patients with B-cell ...

The following is a summary of “BCMA CAR-T therapy as salvage therapy in patients with plasmablastic myeloma,” published in ...

Experts discuss why it is critical to have standardized protocols in place for managing cytokine release syndrome (CRS) in patients receiving bispecific antibodies, outlining the key components of an ...

Several studies have been conducted, but questions remain about where such therapies will fit into multiple myeloma treatment ...

By fighting off pathogens, the specialized cells of our immune systems help to keep us healthy and free of infectious diseases. Immunotherapies teach those same cells to recognize and destroy cancer.

Sponsored content brought to you by In the rapidly advancing field of immuno-oncology research, there has been increasing ...

Regarding myeloma, Burke also shares his experience with myeloma BsAbs, saying, “I follow the drug label, administer the drug ...